(NASDAQ: EVAX) Evaxion Biotech A's forecast annual revenue growth rate of 982.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Evaxion Biotech A's revenue in 2024 is $73,000.On average, 1 Wall Street analysts forecast EVAX's revenue for 2024 to be $530,568,920, with the lowest EVAX revenue forecast at $530,568,920, and the highest EVAX revenue forecast at $530,568,920. On average, 1 Wall Street analysts forecast EVAX's revenue for 2025 to be $2,733,263,689, with the lowest EVAX revenue forecast at $2,733,263,689, and the highest EVAX revenue forecast at $2,733,263,689.
In 2026, EVAX is forecast to generate $3,221,955,562 in revenue, with the lowest revenue forecast at $3,221,955,562 and the highest revenue forecast at $3,221,955,562.